Oscotec Inc (039200) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Oscotec Inc (039200) has a cash flow conversion efficiency ratio of 0.263x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (₩48.00 Billion ≈ $32.53 Million USD) by net assets (₩182.53 Billion ≈ $123.70 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Oscotec Inc liquidity coverage in days to measure how many days the company can operate on defensive assets alone.
Oscotec Inc - Cash Flow Conversion Efficiency Trend (2011–2025)
This chart illustrates how Oscotec Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Oscotec Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Oscotec Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
China Bills Finance Corp
TW:2820
|
0.027x |
|
Qingdao Kutesmart Co Ltd
SHE:300840
|
0.022x |
|
Qingdao Eastsoft Communic Tech
SHE:300183
|
0.004x |
|
Beyondsoft Corp
SHE:002649
|
0.037x |
|
Jiangsu Flowers King
SHG:603007
|
-0.022x |
|
Dilip Buildcon Limited
NSE:DBL
|
-0.441x |
|
Changchun Engley Automobile Industry Co.Ltd.
SHG:601279
|
0.024x |
|
Maravai Lifesciences Holdings Inc
NASDAQ:MRVI
|
-0.035x |
Annual Cash Flow Conversion Efficiency for Oscotec Inc (2011–2025)
The table below shows the annual cash flow conversion efficiency of Oscotec Inc from 2011 to 2025. For the full company profile with market capitalisation and key ratios, see Oscotec Inc (039200) total market value.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | ₩186.85 Billion ≈ $126.62 Million |
₩8.30 Billion ≈ $5.63 Million |
0.044x | +122.59% |
| 2024-12-31 | ₩132.36 Billion ≈ $89.70 Million |
₩-26.03 Billion ≈ $-17.64 Million |
-0.197x | +15.50% |
| 2023-12-31 | ₩94.72 Billion ≈ $64.19 Million |
₩-22.05 Billion ≈ $-14.94 Million |
-0.233x | -7.93% |
| 2022-12-31 | ₩122.51 Billion ≈ $83.02 Million |
₩-26.42 Billion ≈ $-17.91 Million |
-0.216x | +29.04% |
| 2021-12-31 | ₩28.83 Billion ≈ $19.54 Million |
₩-8.76 Billion ≈ $-5.94 Million |
-0.304x | +9.83% |
| 2020-12-31 | ₩53.05 Billion ≈ $35.95 Million |
₩-17.88 Billion ≈ $-12.12 Million |
-0.337x | -63035.38% |
| 2019-12-31 | ₩51.29 Billion ≈ $34.76 Million |
₩27.47 Million ≈ $18.62K |
0.001x | +100.49% |
| 2018-12-31 | ₩46.29 Billion ≈ $31.37 Million |
₩-5.08 Billion ≈ $-3.44 Million |
-0.110x | +36.83% |
| 2017-12-31 | ₩21.24 Billion ≈ $14.40 Million |
₩-3.69 Billion ≈ $-2.50 Million |
-0.174x | +44.31% |
| 2016-12-31 | ₩26.33 Billion ≈ $17.84 Million |
₩-8.21 Billion ≈ $-5.56 Million |
-0.312x | -1397.65% |
| 2015-12-31 | ₩26.92 Billion ≈ $18.24 Million |
₩646.84 Million ≈ $438.35K |
0.024x | +126.68% |
| 2014-12-31 | ₩21.78 Billion ≈ $14.76 Million |
₩-1.96 Billion ≈ $-1.33 Million |
-0.090x | -166.09% |
| 2012-12-31 | ₩24.47 Billion ≈ $16.58 Million |
₩3.34 Billion ≈ $2.26 Million |
0.136x | +832.77% |
| 2011-12-31 | ₩25.73 Billion ≈ $17.43 Million |
₩375.90 Million ≈ $254.74K |
0.015x | -- |
About Oscotec Inc
Oscotec Inc. operates as a clinical stage drug discovery and development company. It develops SYK inhibitor that is in Phase IIa clinical trial to treat rheumatoid arthritis and immune thrombocytopenia; FLT3 inhibitor, which is in Phase I clinical trial for the treatment of acute myeloid leukemia; and EGFR double mutation inhibitor to treat non-small cell lung cancer, as well as Anti-Tau antibody… Read more